Although routine invasive management is recommended in NSTEMI patients, the optimal timing of the procedure is not defined. The aim of this study was to assess outcomes in relation to timing of PCI in NSTEMI patients.
Introduction
Non-ST-elevation acute coronary syndrome (NSTE-ACS) is the most frequent manifestation of acute coronary syndromes (ACS). A routine invasive management (i.e. a diagnostic coronary angiogram followed by revascularization, if appropriate) compared with a selective invasive management not only improves symptoms, but also prognosis, as shown in several meta-analyses. 1 -4 While a routine invasive management now is established in highrisk NSTE-ACS patients, 5 there is still uncertainty regarding the optimal timing of the procedure. Several relatively small studies 6 -11 and one larger trial 12 have assessed early vs. late invasive treatment.
As condensed in two meta-analyses, no difference could be seen with an early invasive vs. a delayed invasive management strategy in terms of all-cause mortality or myocardial infarction. 13, 14 However, in a pre-specified subgroup analysis of the Timing of Intervention in Acute Coronary Syndromes (TIMACS) study, high-risk patients (as defined by having a GRACE score .140) had substantial benefit of early revascularization within 24 h. 12 This subgroup analysis forms the basis of the European Society of Cardiology recommendation of an early invasive management strategy in patients with GRACE score .140.
5
Prior randomized studies are limited by their relatively small sample sizes with low number of events but also the heterogeneity in the timing of intervention. This has partly been overcome by also studying registry data from Can Rapid Risk Stratification of Unstable Angina Patients Suppress Adverse Outcomes With Early Implementation of the American College of Cardiology/American Heart Association Guidelines (CRUSADE) and Global Registry of Acute Coronary Events (GRACE). 15, 16 In these studies, no apparent benefit of early vs. delayed revascularization was seen. Data were collected in the CRUSADE registry from 2001 until 2006 and results from both CRUSADE and GRACE were published about 10 years ago. Thus, these data are not necessarily representative of current clinical practice.
In the present study, we sought to investigate the impact of timing of PCI in patients with NSTEMI using a large, contemporary real-life ACS population from a nation-wide registry.
Methods
The Swedish Web-system for Enhancement and Development of Evidence-based care in Heart disease Evaluated According to Recommended Therapies (SWEDEHEART) registry covers most aspects of cardiac care in Sweden.
All cardiac care units (CCU) in Sweden (n ¼ 72) are connected to RIKS-HIA (Swedish Register of Information and Knowledge about Swedish Heart Intensive Care Admissions; a part of SWEDEHEART), which includes information on all ACS patients treated at all CCUs in Sweden. Similarly, SCAAR (Swedish Coronary Angiography and Angioplasty Registry; also a part of SWEDEHEART) includes information on all coronary angiograms and percutaneous coronary intervention (PCI) procedures performed at all PCI centres in Sweden. Data are entered through a web-based interface, and the reliability of the information is monitored by random checks of source data, with a reported agreement of 96%. 17 The SWEDEHEART database was combined with the Swedish National Patient Register (NPR), and the Swedish population register, to detect recurrent myocardial infarction, and mortality, respectively. The study was approved by the ethics committee in Uppsala.
Study population
In this study, we included patients who were admitted to any Swedish CCU between 1 January 2006 and 31 December 2013 and treated with in-hospital PCI due to NSTEMI (only first entry in database was used, see Supplementary material online, Figure S1 for a selection flowchart).
Outcomes
The pre-specified primary outcome was death from all causes (obtained from the cause of death register), and secondary outcomes were myocardial infarction (MI, obtained from the NPR), stent thrombosis (from SCAAR), and in-hospital severe bleeding (from RIKS-HIA) up to 1 year after hospital admission. Myocardial infarction was assessed from Day 30 after admission to 1 year, as to avoid 'contamination' from the index event. In-hospital severe bleeding (as registered in RIKS-HIA) includes fatal or cerebral bleeding, or bleeding requiring surgery or transfusion.
Statistical analysis
Patient characteristics are reported as medians and 25th-75th percentiles for continuous variables and percentages and frequencies for categorical variables. Unadjusted Kaplan -Meier event rates of the primary and secondary outcomes are plotted in relation to delay of PCI according to three pre-specified cut-offs: within 1 day, within 2 days, within 3 days. The exact times of admission and start of procedure was not registered, only date. Therefore, for example, 'within 2 days' could span from 24 h 1 min delay to 47 h 59 min delay. In the adjusted analyses, mixed effects Cox models were created for each of the above cut-offs, with the following covariates: age (entered as a restricted cubic spline), gender, hypertension, treating hospital (entered as a random effect variable), diabetes, hyperlipidaemia, smoking, prior coronary artery bypass surgery (CABG), prior PCI, previous stroke, peripheral arterial disease, previous cancer, PCI access (i.e. right radial, left radial, femoral from radial, femoral or other), estimated glomerular filtration rate (GFR), angiography findings, stent treatment, number of placed stents, acuteness of the procedure, cardiogenic shock, serious comorbidities that limit treatment (i.e. cancer, dementia, or other serious disease), glycoprotein IIb/IIIa inhibitor use. Event rates and hazard ratios (HR) with 95% confidence intervals (CI) are presented for the primary and secondary outcomes. For bleeding, no time-to-event data were available. Thus, for each component of severe in-hospital bleeding, percentages and frequencies are presented.
Multiple imputation of missing values was performed by chained equations, with 15 imputations. The covariates with most missing values were smoking status and estimated GFR ( 4% missing in each, see Supplementary material online, Table S1 for full information on missing values).
The baseline covariate profile was sufficiently balanced over the two delay groups (for all three splits of time) for using the mixed effects Cox model directly on the full population. In addition, as a sensitivity analysis, we estimated the effect of early PCI via 1-1 propensity score matching, where the above covariates were used also to estimate the propensity scores.
The statistical software R version 3.2.2 (R Core Team, 2015) was used for all analyses, employing the coxme package. 18 
Results

Patients
A total of 40 494 patients were included in the study. The baseline characteristics are shown in Table 1 . Patients who received delayed PCI were older, and had a slightly higher prevalence of comorbidities, e.g. hypertension, hyperlipidaemia, diabetes, and prior stroke. The proportion of patients with male gender was marginally higher in those who received early PCI.
Angiographic findings were similar in patients who received early vs. delayed PCI, and the number of stents used was similar. However, femoral access was used more commonly in those who received delayed PCI.
Primary outcome: death from all causes
The primary outcome of death from all causes occurred less frequently in patients who underwent early PCI as compared with patients receiving delayed PCI, across all three cut-offs to define 'early' (Figures 1-3) .
In the multivariable analyses, early PCI was associated with a reduction in the primary outcome using all three cut-offs to define early; within 1 day: HR 0.89 (95% CI 0.80 -0.98, P ¼ 0.018), 2 days: HR 0.78 (95% CI 0.71 -0.86, P , 0.001), and within 3 days: HR 0.75 (95% CI 0.68-0.84, P , 0.001) ( Table 2) . Results of the sensitivity analyses were similar to the main analyses in direction and magnitude (Supplementary material online) . 
Secondary outcomes
For recurrent MI, there was a similarly lower incidence in patients receiving early vs. delayed PCI (Figures 1 -3) . The benefit of early PCI was seen in the multivariable analyses when using the cut-offs of 2 or 3 days, but not using the 1-day cut-off.
The rates of stent thrombosis did not differ between groups, regardless of delay time from admission to PCI (Table 2) .
Overall, reported severe in-hospital bleeding was uncommon. Deadly bleeding was only captured in 5 out of 40 407 patients. Bleeding requiring surgery or transfusion occurred in 1% of patients.
In patients receiving delayed PCI, bleeding requiring surgery or transfusion tended to be higher than in those treated with early PCI (Table 3) .
Discussion
In this large, contemporary real-world study of outcomes in relation to timing of PCI in NSTE-ACS patients, early PCI was associated with lower risk of both death from all causes and recurrent MI. For the 1-day cut-off, the Kaplan -Meier curves for mortality ( Figure 1) were overlapping for approximately the first 60 days. This may be due to an accumulation of patients who are at very high risk (e.g. those with severe heart failure, hemodynamic instability, refractory angina or patients with life-threatening ventricular arrhythmia) where an urgent invasive management strategy is recommended. 5 This is a group of patients who are at a very high ischaemic risk and generally not included in clinical trials.
Although it is widely accepted that coronary angiography followed by revascularization in NSTE-ACS prevents recurrent ischaemia and improves outcomes, there is inconsistency in the results from previous studies on the benefit of an early invasive strategy. In several of the smaller clinical trials (of between 142 and 815 patients), no benefit in terms of ischaemic outcomes was seen with an early invasive management, 6 -9,11 whereas reduced ischaemic events were seen in studies by Zhang et al., 10 Milosevic et al. 19 and in patients with a GRACE score .140 included in TIMACS. 12 In the older registry data from CRUSADE and GRACE, no apparent benefit with early invasive management was seen. 15, 16 In other Timing of PCI in NSTEMI observational data [post hoc analyses from the RCTs SYNERGY (Superior Yield of the New Strategy of Enoxaparin, Revascularization, and Glycoprotein IIb/IIIa Inhibitors) and ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy)], early invasive management was associated with reductions in ischaemic events. 20, 21 In SYNERGY, invasive management within 6 h was associated with lower rates of the composite of death/MI 20 and in ACU-ITY, a delay of invasive management .24 h was an independent predictor of adverse outcome, including mortality. 21 The present study adds additional information from a large, contemporary, nation-wide cohort, where the results correspond with the more recent of the above-mentioned studies. Furthermore, our study reflects routine clinical practice and is by that not limited by the usually very narrow risk spectrum of patients in randomized clinical trials. During the last decade, several advancements in the management of ACS patients have been made; improved stent technology, 22 an increasing tendency towards using primarily a radial approach rather than femoral for PCI, improving safety of the procedure 23, 24 , and more effective, rapid-acting anti-thrombotic therapy. 25, 26 We show that early PCI for NSTEMI is safe (the reported bleeding rates were very low) and associated with better outcomes in a broad NSTEMI population.
Limitations
This was a study from a registry, with its inherent limitations (e.g. selection bias, and differences in groups with regard to baseline characteristics, also unmeasured bias). One specific limitation is that the reason for delayed arrival in the catheter lab was not registered in the database. While every effort was made to adjust for possible confounding variables, the risk of residual confounding is acknowledged. As such, the results should be considered hypothesis generating. In addition, the resolution regarding delay times is in days, not in hours or minutes, which leads to additional uncertainty regarding the delay time. Furthermore, the bleeding information registered in SWEDEHEART is limited. Therefore, a potential for underreporting of bleeding events is acknowledged. And, finally, MI events were assessed from 30 days onward, as to avoid 'contamination' from the index event. Thus, potential differences in early MIs could not be assessed.
Conclusion
In patients undergoing PCI for NSTEMI, early invasive treatment is associated with lower rates of ischaemic events at 1 year.
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